Novo Nordisk A/S (NYSE:NVO) Shares Gap Down to $130.12

Novo Nordisk A/S (NYSE:NVO)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $130.12, but opened at $122.69. Novo Nordisk A/S shares last traded at $122.36, with a volume of 2,185,405 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Argus increased their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Price Performance

The company’s 50-day simple moving average is $137.93 and its 200 day simple moving average is $129.65. The company has a market capitalization of $534.33 billion, a P/E ratio of 42.03, a P/E/G ratio of 1.33 and a beta of 0.41. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17.

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter valued at $26,000. Finally, Orion Capital Management LLC bought a new position in Novo Nordisk A/S in the 1st quarter worth $26,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.